linjc16/ctgov huggingface dataset:
Left Renal Vein Division for Juxtarenal Aortic Exposure

Study Overview
=================
Brief Summary
-----------------
Retrospective study on the outcome of the renal function in patients operated because of juxtarenal aortic aneurysms.

Official Title
-----------------
Left Renal Vein Division for Juxtarenal Aortic Exposure: Renal Function and Role of the Communicating Lumbar Vein

Conditions
-----------------
Aortic Aneurysm, Juxtarenal Aortic Aneurysm, Renal Function Disorder

Intervention / Treatment
-----------------
* Procedure: Exclusion of the aortic aneurysm.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Only patients who went for a planned operation because of a juxtarenal aortic aneurysm were included in this retrospective analysis. Exclusion Criteria: Emergency surgery Rupture Pending rupture

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br>Group of patients in whom the left renal vein was divided for exposure of the aorta. | Procedure: Exclusion of the aortic aneurysm.<br>* Surgical procedure in which an aortic aneurysm is excluded.<br>|
| A+<br>Subgroup of group A in whom a communicating vein to the left ascending lumbar vein was present. | Procedure: Exclusion of the aortic aneurysm.<br>* Surgical procedure in which an aortic aneurysm is excluded.<br>|
| A-<br>Subgroup of group A in whom a communicating vein to the left ascending lumbar vein was not present. | Procedure: Exclusion of the aortic aneurysm.<br>* Surgical procedure in which an aortic aneurysm is excluded.<br>|
| B<br>Group of patients in whom the left renal vein was mobilized but not divided for exposure of the aorta. | Procedure: Exclusion of the aortic aneurysm.<br>* Surgical procedure in which an aortic aneurysm is excluded.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Renal function after surgery. | The level of creatinine in the blood was measured after surgery at several time points. | 24 months |
Efficacy of Salivary Bacteria and Post Brushing

Study Overview
=================
Brief Summary
-----------------
Research study to compare the effects of brushing with two commercially available toothpastes on salivary bacteria after brushing

Official Title
-----------------
Efficacy of Salivary Bacteria and Post Brushing

Conditions
-----------------
Salivary Bacteria Levels

Intervention / Treatment
-----------------
* Drug: Fluoride
* Drug: Triclosan/Fluoride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female volunteers 18-65 years of age Good general health Must sign informed consent form Must discontinue oral hygiene on the mornings of each appointment and between sampling periods. No history of allergy to personal care consumer products, or their ingredients, relevant to any ingredient in the test products as determined by the dental/medical professional monitoring the study. Exclusion Criteria: Medical condition which requires pre-medication prior to dental procedures/visits Medical condition which precludes eating/drinking for 12 hrs. History of allergy to common dentifrice ingredients Subjects unable or unwilling to sign the informed consent form. Moderate or advanced periodontal disease. 2 or more decayed untreated dental sites at screening. Other disease of the hard or soft oral tissues. Impaired salivary function (e.g. Sjogren's syndrome or head and neck irradiation). Use of medications that can currently affect salivary flow Current use of antibiotics Use of antibiotics or antimicrobial drugs within 30 days prior to study visit #1. Pregnant or nursing women. Participation in any other clinical study within 30 days prior to enrollment into this study. Use of tobacco products Subjects who must receive dental treatment during the study dates. Current use of Antibiotics for any purpose. Immune compromised individuals (HIV,AIDS, immuno suppressive drug therapy)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: A<br>fluoride toothpaste control | Drug: Fluoride<br>* Whole mouth brushing for 7 days<br>* Other names: fluoride toothpaste (Colgate Great Regular Flavor toothpaste);|
| Active Comparator: B<br>triclosan/fluoride toothpaste | Drug: Triclosan/Fluoride<br>* Brush whole mouth twice daily for 7 days<br>* Other names: triclosan/fluoride toothpaste (Colgate Total toothpaste);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CFU (Colony Forming Units) | Total number of salivary bacterial colony forming units (lower number = less colonies present) | 4 hours |
Regulation of Placental Vascular Reactivity in Pregnancy-induced Hypertension

Study Overview
=================
Brief Summary
-----------------
To elucidate the role of an imbalance in vasodilator prostacyclin (PGI2) and vasoconstrictor thromboxane (TxA2) in pregnancy-induced hypertension

Detailed Description
-----------------
BACKGROUND: Pregnancy-induced hypertension (PIH) is associated with increased fetal and neonatal morbidity and mortality possibly resulting from hypoxia in utero. The primary pathology of PIH involves a reduction in uteroplacental blood flow but modern imaging techniques have now shown that increased impedance of the fetal-placental circulation and hence reduced blood flow can also be found in PIH. This may represent a direct effect of hypoxia or be a fetal adaptation to increase placental oxygen extraction to relieve hypoxia. The fetal-placental circulation is regulated by humoral agents and vascular pressure. An imbalance of vasodilator prostacyclin (PGI2) and vasoconstrictor thromboxane (TxA2) production is reported to underlie the vasoconstriction seen in PIH. The study resulted from the 1986 release of a Request for Applications for Research on Hypertension in Pregnancy by the National Heart, Lung, and Blood Institute and the National Institute of Child Health and Human Development. DESIGN NARRATIVE: The fetal-placental circulations of perfused human placental cotyledons from normotensive and pregnancy-induced hypertensive pregnancies were used to determine if an imbalance in PGI2/TxA2 production existed and its relationship to the responses of the fetal-placental circulation to vasoconstriction. Studies were also conducted on the effects of hypocalcemia and hypomagnesemia, hypoxia, and drugs. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Cardiovascular Diseases, Heart Diseases, Hypertension, Pregnancy Toxemias

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Validation of the Turkish Version of the Pain Sensitivity Questionnaire

Study Overview
=================
Brief Summary
-----------------
The Pain Sensitivity Questionnaire(PSQ) is a self-rating measure for the assessment of pain sensitivity and has been developed by Dr. R. Ruscheweyh in Germany. It consists of 17 items rated from 0, not at all painful to 10, most severe pain imaginable. The validation of the Turkish version of PSQ is needed, in order to measure pain sensitivity among Turkish people.

Official Title
-----------------
Validation of the Turkish Version of the Pain Sensitivity Questionnaire in Patients With Chronic Pain

Conditions
-----------------
Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA 1-2 adult chronic low back pain patients having pain for greater than 3 months Exclusion Criteria: Failed back surgery syndrome, Morbid obesity (body mass index, >40), Being a non-Turkish speaker, Substance abuse disorder, Major psychiatric disorder (eg, severe depression, bipolar disorder, Axis II personality disorder, and schizophrenia).

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of pain intensity in Turkish people using The Turkish version of the PSQ | Measurement of pain intensity in Turkish people using The Turkish version of the PSQ, consisting of 17 items, describing different daily life situations with a scoring from 0(not painful) to 10 (worst pain imaginable) on a numeric rating scale. A PSQ total score is between 0-10, the higher score, the more patient's pain sensitivity. | 1 day | 
| Pain Catastrophizing Scale | This scale is used in order to assess the state of mind of patients in pain through a comprehensive evaluation instrument that encompasses the different perspectives on catastrophizing. It is a self-report measure, consisting of 13 items scored from 0 to 4, resulting in a total possible score of 52.24 The higher the score, the more catastrophizing thoughts are present. | 1 day | 
| Beck Anxiety Inventory | This scale, consisting of 21 items, is a self-report measure of anxiety. Score of 0-21 shows low anxiety. Score of 22-35 shows moderate anxiety. Score of 36 and above shows potentially concerning levels of anxiety. | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pain sensitivity
Pituitary Adenoma and Serum Lipid

Study Overview
=================
Brief Summary
-----------------
Pituitary adenomas are usually benign monoclonal neoplasms caused by a mixture of pituicyte alterations together with a changed endocrine and paracrine regulatory milieu. Thus, it can cause serious health problems such as abnormal target organ function, pain, disability and even death. In clinical practice, we found many patients with pituitary adenomas are usually accompanied by hyperlipidemia, which is the main cause of cardiovascular diseases. However, it has been unclear if there is an association between pituitary adenomas and serum lipid profile. In the present study, we aim to focus on the patients with pituitary adenomas and their lipid profile before and after operation including first occurrence and recurrence.

Official Title
-----------------
Effects of Pituitary Adenoma Resection on Serum Lipid Level

Conditions
-----------------
Pituitary Adenoma 1, Acth-Secreting

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with pituitary adenomas All adenomas were resected by transsphenoidal surgery and identified by histological diagnoses. Exclusion Criteria: Missing vital data, such as age, gender, serum lipid profile, pathology reports; Complications or conditions that affect pituitary status and lipid metabolism, such as pregnancy, malignant adenomas or severe hepatic or renal dysfunction and Use of any medication that affects the pituitary or lipid metabolism, including statins, fibrates, thyroid hormones, anti-thyroid drugs, iodine, amiodarone, alemtuzumab, lithium, tyrosine kinase inhibitors, interferon, estrogens, androgens,glucocorticoids, nonsteroidal anti-inflammatory drugs, antiepileptic drugs, rifampicin, furosemide, heparin or β-adrenoceptor blockers in the past 3 months.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with pituitary adenomas resection<br>Patients suffers from pituitary adenomas and undergo transsphenoidal surgery for at least once | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in serum lipid levels |  | Measured at pre-operative and 6 months after operation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Resection, Pituitary, Pituitary Adenoma, Serum Lipid Levels, Recurrence
3TC (Lamivudine; GR109714X) Open-Label Program

Study Overview
=================
Brief Summary
-----------------
To make lamivudine (3TC) available to patients with progressive, symptomatic HIV disease who cannot participate in a controlled clinical trial and who are refractory or unable to tolerate other therapies. To collect data pertaining to the safety of 3TC at two dose levels. To evaluate the effect of 3TC on markers of hepatitis B in co-infected patients at five to ten selected sites.

Detailed Description
-----------------
Patients 12 years and older are randomized to receive one of two doses of 3TC for a duration determined by the patient's physician or until termination of the program. Patients < 12 years receive a lower dose of 3TC. Patients are followed monthly. For selected sites only, serum samples are collected every 3 months from patients identified as HBsAg positive. PER 02/28/95 AMENDMENT: Patients enrolled prior to 3/1/95 may remain on their assigned monotherapy dose or change to combination therapy with 3TC and zidovudine.

Official Title
-----------------
3TC (Lamivudine; GR109714X) Open-Label Program

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Lamivudine
* Drug: Zidovudine


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients must: Have progressive, symptomatic HIV disease. Have a mean CD4 count <= 99 cells/mm3 for adults and <= 300 cells/mm3 for children (original design was CD4 count <= 300 cells/mm3 for both adults and children). Be unable to participate in a controlled trial. Be refractory to or unable to tolerate other therapies. Be able to attend clinic on a monthly schedule. Have consent of parent or guardian if under the age of consent. NOTE: If a pregnant or breast-feeding woman requests enrollment, her physician should contact Glaxo staff directly to discuss the case. Practice of unsafe sex.

Ages Eligible for Study
-----------------
Minimum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lamivudine|nan|
|Drug: Zidovudine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Drug Therapy, Combination, Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Antiviral Agents, Zidovudine
Effectiveness of a Procedure for Previously Failed Glaucoma Surgery

Study Overview
=================
Brief Summary
-----------------
Transconjunctival mitomycin-C in needle bleb revision may be an effective procedure to treat cases with a previously failed trabeculectomy. We will investigate approximately 100 consecutive cases with follow up of up to 9 years. We anticipate that this procedure is an effective, safe, and appropriate option for successful glaucoma treatment.

Detailed Description
-----------------
The healing process after filtering surgery for glaucoma may cause an unsuccessful outcome for the trabeculectomy procedure. In order to control the rising intraocular pressure due to the failed trabeculectomy, medications may be restarted and/or filtering surgery may need to be repeated. Our primary research showed that transconjunctival mitomycin-C in needle bleb revision may be an effective procedure to control this situation. This retrospective study will follow over 100 patients from May 1997 to May 2006. This long-term follow up will help assess the future role of this technique in glaucoma practices.

Official Title
-----------------
Efficacy of Transconjunctival Mitomycin-C in Needle Revisions of Failing Trabeculectomy

Conditions
-----------------
Glaucoma

Intervention / Treatment
-----------------
* Procedure: Glaucoma surgery- Bleb revision


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of glaucoma Failed filtering procedures- defined as intraocular pressure exceeded target pressure thus inducing possible further optic nerve damage Exclusion Criteria: - Needling combined with other ocular surgical or laser treatments

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Glaucoma surgery- Bleb revision|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
glaucoma, trabeculectomy, filtering bleb revision, intraocular pressure, needling procedure, mitomycin C
Spatial Frequency Domain Imaging (SFD) for Assessment of Diabetic Foot Ulcer Development and Healing

Study Overview
=================
Brief Summary
-----------------
This study is designed to evaluate the ability of Spatial Frequency Domain Imaging (SFDI) to measure perfusion in lower extremities for prediction of both healing and formation of diabetic foot ulcers. The investigators will perform longitudinal imaging (for 12 months) in two cohorts of subjects

Official Title
-----------------
Spatial Frequency Domain Imaging (SFD) for Assessment of Diabetic Foot Ulcer Development and Healing

Conditions
-----------------
Diabetic Foot Ulcer

Intervention / Treatment
-----------------
* Device: Spatial Frequency Domain Imaging (SFDI)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: I. Will be followed up in clinic on monthly basis for the next 12 months per standard of care II. Belong to one of the two target groups Subjects with an existing diabetic foot ulcer Subjects determined at risk for an ulcer Exclusion Criteria: History of heart failure Rheumatoid arthritis Pregnant or lactating women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| With Existing Diabetic Ulcers<br>Current DFU | Device: Spatial Frequency Domain Imaging (SFDI)<br>* Observational study to measure perfusion in lower extremities for prediction of both healing and formation of diabetic foot ulcers using Reflect RS<br>* Other names: Reflect RS;|
| Diabetic Ulcers in remission<br>DFU in remission | Device: Spatial Frequency Domain Imaging (SFDI)<br>* Observational study to measure perfusion in lower extremities for prediction of both healing and formation of diabetic foot ulcers using Reflect RS<br>* Other names: Reflect RS;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perfusion in lower extremities | SFDI data outputs | 12-month |
Examination of the Link Between Sun Exposure Routine and Bacteria Population of the Skin

Study Overview
=================
Brief Summary
-----------------
These days many studies are conducted testing the symbiosis between the bacteria population to the human body's functioning. The research of the connection between the skin condition and the bacteria population is in its early stages. There is a characterization of different bacteria for different body areas depending on their composition, humidity etc. In addition, there are preliminary findings of biological receptors that react to the contact with bacteria on the surface of the skin and turn on the immune system, awakening it to cope with the new invader. Based on the above information, the investigators hypothesis is that there is a connection between the degrees of sun exposure of individuals to the growing of beneficial bacteria populations on the surface of the skin. The study will compare between the bacteria population on the skin of Israeli subjects, divided to two groups, one with an excessive exposure to the sun on a daily basis, (such as agricultural workers, lifeguards, construction, etc.), and the other of the office worker who spend most of the day in a closed shaded room.

Official Title
-----------------
Examination of the Link Between Sun Exposure Routine and Bacteria Population of the Skin

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Behavioral: Sun exposure routine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy volunteers between the age of 20-60. Exclusion Criteria: Pregnant or lactating women. Volunteers with a known allergy to one of the tested materials or to their ingredients. Treatment with medication such as anti-inflammatories, antihistamines,corticosteroids, systemically or topically applied, unless stopped for 2 weeks prior to the trial in the case of systemic treatment and 3 days in the case of topical treatment.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| outdoor workers<br>Subjects with an excessive exposure to the sun on a daily basis | Behavioral: Sun exposure routine<br> <br> |
| office workers<br>Subjects who spend most of the day in a closed shaded room | Behavioral: Sun exposure routine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Scanning the bacteria population of the surface of the skin by using swab on the cheek area. The samples of bacteria will be characterized by genetic sequencing. |  | 6 months |